Table 4. Adverse events between TAM and AI in the ET group.
Table 4—source data 1. Adverse events in the endocrine therapy (ET) group.
elife-83045-table4-data1.xlsx (15MB, xlsx)
| Adverse events | TAM (N=551) | AI (N=223) |
|---|---|---|
| Total | 212 (38%) | 76 (34%) |
| Musculoskeletal symptoms | 61 (11%) | 52 (23%) |
| Vasomotor symptoms | 42 (8%) | 12 (5%) |
| Gynecological events | 113 (21%) | 5 (2%) |
| Cardiovascular events | 26 (5%) | 12 (5%) |
| Abnormal liver function | 10 (2%) | 4 (2%) |
Notes: TAM, tamoxifen; AI, aromatase inhibitor; ET, endocrine therapy.
Source files available in Table 4—source data 1.